• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Metformin adherence and the risk of cardiovascular disease: a population-based cohort study
CONCLUSIONS: This study revealed that metformin adherence in patients with T2DM who required a first-line treatment may reduce the risk of subsequent CVD. Despite the availability of numerous novel antiglycemic agents, metformin adherence by patients who require a combination of antiglycemic agents provides an additional benefit of CVD protection.PMID:37051071 | PMC:PMC10084537 | DOI:10.1177/20406223231163115
Source: Adv Data - April 13, 2023 Category: Epidemiology Authors: Shun-Fan Yu Chien-Tai Hong Wan-Ting Chen Lung Chan Li-Nien Chien Source Type: research

Comparison of the effects on cardiovascular events between use of metformin and dipeptidyl peptidase-4 inhibitors as the first-line hypoglycaemic agents in Japanese patients with type 2 diabetes mellitus: a claims database analysis
Conclusions Patients who received metformin as first-line therapy may have reduced cardiovascular events than those receiving DPP-4i. This study conforms to previous Japanese database studies, despite the consideration of its limitation being an observational design.
Source: BMJ Open - March 11, 2022 Category: General Medicine Authors: Nishimura, R., Takeshima, T., Iwasaki, K., Aoi, S. Tags: Open access, Diabetes and Endocrinology Source Type: research

Cardiovascular Safety of Sodium Glucose Cotransporter 2 Inhibitors as Add-on to Metformin Monotherapy in Patients with Type 2 Diabetes Mellitus.
Conclusion: SGLT2 inhibitors can be a good second-line drug to reduce the incidence of cardiovascular diseases compared with DPP-4 inhibitors or sulfonylureas in people with type 2 diabetes mellitus. PMID: 33120439 [PubMed - as supplied by publisher]
Source: Diabetes and Metabolism Journal - October 31, 2020 Category: Endocrinology Tags: Diabetes Metab J Source Type: research

Budget impact analysis for dapagliflozin in type 2 diabetes in Egypt.
Conclusion: Treating T2DM patients using dapagliflozin instead of conventional medications, maximizes patient's benefits and decreases total costs due to drug cost offsets from fewer cardiovascular and renal events. The adoption of dapagliflozin is a budget-saving treatment option, resulting in substantial population-level health gains due to reduced event rate and cost savings from the perspective of the national healthcare system. PMID: 32364032 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - May 5, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Association of Traditional Chinese Medicine Therapy and the Risk of Vascular Complications in Patients With Type II Diabetes Mellitus: A Nationwide, Retrospective, Taiwanese-Registry, Cohort Study
This study investigated whether the concurrent TCM treatment reduces the risk of vascular complications in T2DM patients by using a large population from National Health Insurance Research Database (NHIRD). We identified 33,457 adult patients with newly diagnosed T2DM using anti-diabetic agents from a random sample of one million beneficiaries in the NHIRD between January 1, 2000 and December 31, 2011. We recruited 1049 TCM users (received TCM over 30 days with a diagnosis of T2DM) and randomly selected 4092 controls as the non-TCM cohort at a ratio of 1:4 frequency-matched by age, sex, hypertension, hyperlipidemia, and i...
Source: Medicine - January 1, 2016 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research

Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
Conclusion: Compared with sulfonylureas, DPP-4 inhibitors were associated with lower risks for all-cause death, MACEs, ischemic stroke, and hypoglycemia when used as add-ons to metformin therapy. Primary Funding Source: None. PMID: 26457538 [PubMed - as supplied by publisher]
Source: Annals of Internal Medicine - October 13, 2015 Category: Internal Medicine Authors: Ou SM, Shih CJ, Chao PW, Chu H, Kuo SC, Lee YJ, Wang SJ, Yang CY, Lin CC, Chen TJ, Tarng DC, Li SY, Chen YT Tags: Ann Intern Med Source Type: research

Oral hypoglycaemic agents and the development of non‐fatal cardiovascular events in patients with type 2 diabetes mellitus
ConclusionsT2DM patients taking metformin and glimepiride are at lower risk of non‐fatal cardiovascular events than those taking glyburide. Copyright © 2013 John Wiley & Sons, Ltd.
Source: Diabetes/Metabolism Research and Reviews - November 14, 2013 Category: Endocrinology Authors: Yi‐Chih Hung, Che‐Chen Lin, Tzu‐Yuan Wang, Man‐Ping Chang, Fung‐Chang Sung, Ching‐Chu Chen Tags: Research Article Source Type: research

Oral hypoglycemic agents and the development of non‐fatal cardiovascular events in patients with type 2 diabetes mellitus
ConclusionsT2DM patients taking metformin and glimepiride are at lowered risk of non‐fatal CV events than those taking glyburide. This article is protected by copyright. All rights reserved.
Source: Diabetes/Metabolism Research and Reviews - July 1, 2013 Category: Endocrinology Authors: Yi‐Chih Hung, Che‐Chen Lin, Tzu‐Yuan Wang, Man‐Ping Chang, Fung‐Chang Sung, Ching‐Chu Chen Tags: Research Article Source Type: research